Essex Bio-Technology 1061.HK · HKD

Its shares trade on HKEX under the ticker 1061.HK. It has been listed since 27 June 2001. In the fiscal year to 31 December 2025, it reported revenue of HK$1.81bn and net income of HK$318.1m. At that date it held total assets of HK$3.49bn and shareholders' equity of HK$2.41bn.

Essex Bio-Technology Ltd. is an investment holding company, which engages in the development, manufacture and sale of biopharmaceutical products. The company employs 1,110 full-time employees The company went IPO on 2001-06-27. The firm develops biopharmaceutical drugs based on recombinant deoxyribonucleic acid (DNA) technology. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin. The firm operates through two business segments. The Pharmaceutical Products segment is engaged in the development, manufacture and sales of pharmaceutical products. The Provision of Marketing Services segment is involved in the distribution of third party products and provision of marketing services to such third party’s products.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Mia Je NgiamExecutive Chairman of the BoardHK$3.3m
• Dr. Qi XueChief Scientific Officer
• Mr. Zanshun ZhengSenior Managing Director
• Mr. Haizhou FangManaging Director, General Manager, Executive DirectorHK$2.0m
• Ms. Lai Man YauExecutive Director, Secretary, since 2001HK$1.9m
• Mr. Hian Leng Malcolm NgiamExecutive Director, since 2020HK$1.8m
• Mr. Chi Ying FungIndependent Non-Executive DirectorHK$250,000
• Mr. Man Sing YanIndependent Non-Executive Director
• Mme. Mee Mooi YeowIndependent Non-Executive DirectorHK$220,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.